Publications

Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.. Cancer Discov.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2018.  A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.. Clin Cancer Res.

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A et al..  2015.  The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.. Cell Rep. 12(6):922-36.

Choe H, Sboner A, Beltran H, Nanus D, Tagawa ST.  2016.  PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma.. Thromb Res. 140 Suppl 1:S192.

Attard G, Beltran H.  2015.  Prioritizing precision medicine for prostate cancer.. Ann Oncol. 26(6):1041-2.

Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera J-M, Reuter VE, Robinson BD, Troncoso P, Rubin MA.  2014.  Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.. Am J Surg Pathol. 38(6):756-67.

Sternberg CN, Beltran H.  2017.  Prostate cancer in 2016: Improved outcomes and precision medicine come within reach.. Nat Rev Urol. 14(2):71-72.

Beltran H, Demichelis F.  2015.  Prostate cancer: Intrapatient heterogeneity in prostate cancer.. Nat Rev Urol. 12(8):430-1.

Park K, Chen Z, MacDonald TY, Siddiqui J, Ye H, Erbersdobler A, Shevchuk MM, Robinson BD, Sanda MG, Chinnaiyan AM et al..  2014.  Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.. Hum Pathol. 45(10):2136-43.

Baca SC, Prandi D, Lawrence MS, Mosquera JMiguel, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al..  2013.  Punctuated evolution of prostate cancer genomes.. Cell. 153(3):666-77.

Ku SYu, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez ECortes, Wang J et al..  2017.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.. Science. 355(6320):78-83.

Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen C-C, Wongvipat J, Ku S-Y, Gao D, Cao Z et al..  2017.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.. Science. 355(6320):84-88.

Klimstra DS, Beltran H, Lilenbaum R, Bergsland E.  2015.  The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.. Am Soc Clin Oncol Educ Book. :92-103.

Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H, Mo F, Beltran H, Gleave M, Wang Y et al..  2017.  SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.. Eur Urol. 71(1):68-78.

Beltran H, Yelensky R, Frampton GM, Park K, , MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM et al..  2013.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.. Eur Urol. 63(5):920-6.

O'Rourke KP, Loizou E, Livshits G, Schatoff EM, Baslan T, Manchado E, Simon J, Romesser PB, Leach B, Han T et al..  2017.  Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer.. Nat Biotechnol. 35(6):577-582.

Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera J-M, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA et al..  2014.  Unraveling the clonal hierarchy of somatic genomic aberrations.. Genome Biol. 15(8):439.

Beltran H.  2016.  Update on the biology and management of neuroendocrine prostate cancer.. Clin Adv Hematol Oncol. 14(7):513-5.

Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.. JAMA Oncol. 1(4):466-74.